<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="discussion" dtd-version="3.0" xml:lang="EN">
	<front>
		<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">ppat</journal-id><journal-id journal-id-type="allenpress-id">plpa</journal-id><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher>
				<publisher-name>Public Library of Science</publisher-name>
				<publisher-loc>San Francisco, USA</publisher-loc>
			</publisher></journal-meta>
		<article-meta><article-id pub-id-type="doi">10.1371/journal.ppat.0030113</article-id><article-id pub-id-type="publisher-id">07-PLPA-OP-0282R2</article-id><article-id pub-id-type="sici">plpa-03-09-07</article-id><article-categories>
				<subj-group subj-group-type="heading">
					<subject>Opinion</subject>
				</subj-group>
				<subj-group subj-group-type="Discipline">
					<subject>Biochemistry</subject>
					<subject>Microbiology</subject>
				</subj-group>
				<subj-group subj-group-type="System Taxonomy">
					<subject>Plasmodium</subject>
				</subj-group>
			</article-categories><title-group><article-title>Botulinum Neurotoxin Heavy Chain Belt as an Intramolecular Chaperone for the Light Chain</article-title><alt-title alt-title-type="running-head">Plasmodium Rhomboid Proteases</alt-title></title-group><contrib-group>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Brunger</surname>
						<given-names>Axel T</given-names>
					</name>
					<xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Breidenbach</surname>
						<given-names>Mark A</given-names>
					</name>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Jin</surname>
						<given-names>Rongsheng</given-names>
					</name>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Fischer</surname>
						<given-names>Audrey</given-names>
					</name>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Santos</surname>
						<given-names>Jose S</given-names>
					</name>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
				<contrib contrib-type="author" xlink:type="simple">
					<name name-style="western">
						<surname>Montal</surname>
						<given-names>Mauricio</given-names>
					</name>
					<xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
					<xref ref-type="fn" rid="n103"/>
				</contrib>
			</contrib-group><contrib-group>
				<contrib contrib-type="editor" xlink:type="simple">
					<name name-style="western">
						<surname>Manchester</surname>
						<given-names>Marianne</given-names>
					</name>
					<role>Editor</role><xref ref-type="aff" rid="edit1"/>
				</contrib>
			</contrib-group><aff id="edit1">The Scripps Research Institute, United States of America</aff><author-notes>
			<fn fn-type="con" id="ack1">
				<p>ATB and MM conceived the hypotheses. ATB, MAB, RJ, AF, JSS, and MM wrote the paper.</p>
			</fn>			<fn fn-type="current-aff" id="n103">
				<p>Axel T. Brunger, Mark A. Breidenbach, and Rongsheng Jin are with the Departments of Molecular and Cellular Physiology, Neurology and Neurological Science, Structural Biology, and Stanford Synchrotron Radiation Laboratory, Stanford University, Stanford, California, United States of America, and the Howard Hughes Medical Institute, Stanford, California, United States of America. Mark A. Breidenbach is currently with the Department of Chemistry, University of California, Berkeley, California, United States of America. Audrey Fischer, Jose S. Santos, and Mauricio Montal are with the Section of Neurobiology, University of California San Diego, La Jolla, California, United States of America.</p>
			</fn>				<corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">brunger@stanford.edu</email> (ATB), <email xlink:type="simple">mmontal@ucsd.edu</email> (MM)</corresp>
			<fn fn-type="conflict" id="ack3">
				<p> The authors have declared that no competing interests exist.</p>
			</fn></author-notes><pub-date pub-type="ppub">
				<month>9</month>
				<year>2007</year>
			</pub-date><pub-date pub-type="epub">
				<day>28</day>
				<month>09</month>
				<year>2007</year>
			</pub-date><volume>3</volume><issue>9</issue><elocation-id>e113</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2007</copyright-year><copyright-holder>Brunger et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><funding-group><funding-statement>This work was supported by the Department of Defense and Defense Threat Reduction Agency proposal number 3.10024_06_RD_B (to ATB) and by the US Army Medical Research and Materiel Command (DAMD17–02-C-0106 to MM), and by the Pacific Southwest Regional Center of Excellence (AI065359 to MM).</funding-statement></funding-group><counts>
				<page-count count="4"/>
			</counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
				<custom-meta>
					<meta-name>citation</meta-name>
					<meta-value>Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, et al. (2007) Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 3(9): e113. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.ppat.0020113" xlink:type="simple">10.1371/journal.ppat.0020113</ext-link></meta-value>
				</custom-meta>
			</custom-meta-group></article-meta>
	</front>
	<body>
		<sec id="s1">
			<title>Background</title>
			<p>Botulism is a neuroparalytic illness caused by botulinum neurotoxin (BoNT). Seven BoNT serotypes (designated as A to G) are produced by <italic>Clostridium botulinum,</italic> a spore-forming, obligate anaerobic bacterium. BoNT, widely considered the most potent toxin known and a major bioweapon [<xref ref-type="bibr" rid="ppat-0020113-b001">1</xref>], is a potent blocker of synaptic transmission in peripheral cholinergic nervous system synapses, thereby causing paralysis. Based on its exquisitely powerful neuroparalytic activity, BoNT has gained tremendous popularity in the past few years since becoming the first biological toxin (BoNT serotype A) to receive US Food and Drug Administration approval for the treatment of human disease [<xref ref-type="bibr" rid="ppat-0020113-b002">2</xref>].</p>
			<p>Biochemically, BoNTs are synthesized as single polypeptide chains and then cleaved by bacterial proteases into a di-chain molecule linked by a disulfide bond: an ∼50-kDa light chain (LC) and an ∼100-kDa heavy chain (HC). Structurally, BoNTs encompass three modules [<xref ref-type="bibr" rid="ppat-0020113-b003">3</xref>–<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]: the N-terminal LC is a metalloprotease, whereas the HC comprises the translocation domain (the N-terminal segment) and the receptor-binding domain (the C-terminal segment). The modular architecture of the neurotoxin is clearly visible in the crystal structures of BoNT/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] (<xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>A) and BoNT/B [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]. All seven BoNT serotypes exhibit significant amino acid sequence conservation [<xref ref-type="bibr" rid="ppat-0020113-b005">5</xref>], although all are antigenically distinct.</p>
			<fig id="ppat-0020113-g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.ppat.0030113.g001</object-id>
				<label>Figure 1</label>
				<caption>
					<title>Structures of BoNT/A Holotoxin, BoNT/A LC-sn2 Complex, and Overlay of sn2 Segment with Belt Regions of BoNT/A and BoNT/B</title>
					<p>(A) Structure of BoNT/A. The Cα backbone of the LC (left) is represented as cyan ribbons; the purple sphere highlights the catalytic Zn<sup>2+</sup> at the protease active site. The HC belt segment encompassing residues 492–545 is displayed in magenta and the 449–491 region in gold. The HC is depicted in blue, in which the helical module (middle) is the translocation domain, and the two sub-domains consisting primarily of β-strands constitute the receptor-binding domain (right).</p>
					<p>(B) Structure of BoNT/A-LC in complex with the sn2 segment of SNAP-25 [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>]. The Cα backbone of the LC is represented as cyan ribbons and its molecular surface in transparent grey. The sn2 segment is depicted in red and the catalytic Zn<sup>2+</sup> at the active site as a purple sphere.</p>
					<p>(C) Superposition of the structures of the sn2 segment in complex with the LC/A, the HC belt of BoNT/A, and the HC belt of BoNT/B. LC removed for display. For the superposition, the backbone atoms of the LCs were used for the best fit between the structures. sn2 segment depicted in red; overlay of the Cα backbone of BoNT/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] and BoNT/B [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>] belts represented as magenta and lime ribbons. Spheres represent the catalytic Zn<sup>2+</sup> at the active site of BoNT/A (red and magenta) and BoNT/B (lime). All images were rendered with YASARA [<xref ref-type="bibr" rid="ppat-0020113-b040">40</xref>].</p>
				</caption>
				<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.0030113.g001" xlink:type="simple"/>
			</fig>
			<p>It is generally agreed that BoNTs exert their neurotoxic effect by a four-step mechanism [<xref ref-type="bibr" rid="ppat-0020113-b003">3</xref>,<xref ref-type="bibr" rid="ppat-0020113-b007">7</xref>] that involves (1) binding to high-affinity receptors on peripheral nerve endings, (2) receptor-mediated endocytosis, (3) LC translocation across endosomal membranes into the cytosol upon exposure to endosomal pH, and (4) proteolytic degradation of target. The BoNT LCs are sequence-specific endopeptidases that cleave SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. SNAREs form a complex that mediates synaptic vesicle fusion [<xref ref-type="bibr" rid="ppat-0020113-b008">8</xref>–<xref ref-type="bibr" rid="ppat-0020113-b010">10</xref>]. Accordingly, SNARE proteolysis destabilizes or prevents full assembly of the SNARE core complex, abrogating fusion of synaptic vesicles with the plasma membrane, thereby aborting neurotransmitter release [<xref ref-type="bibr" rid="ppat-0020113-b003">3</xref>,<xref ref-type="bibr" rid="ppat-0020113-b011">11</xref>]. BoNT serotypes A, E, and C all cleave the plasma membrane–associated protein SNAP-25 (synaptosome-associated protein of 25 kDa), and serotype C also cleaves the plasma membrane–associated SNARE syntaxin. In contrast, BoNT/B, D, F, and G all proteolyze synaptobrevin, a synaptic vesicle–associated membrane protein, also known as VAMP, at unique sites [<xref ref-type="bibr" rid="ppat-0020113-b003">3</xref>]. The active site region of the BoNT LCs shares structural similarity to the Zn<sup>2+</sup>-metalloprotease thermolysin [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>,<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>,<xref ref-type="bibr" rid="ppat-0020113-b012">12</xref>–<xref ref-type="bibr" rid="ppat-0020113-b017">17</xref>]. In contrast to other Zn<sup>2+</sup>-proteases, the BoNTs require an extended enzyme-substrate interface for optimal catalytic efficiency [<xref ref-type="bibr" rid="ppat-0020113-b018">18</xref>–<xref ref-type="bibr" rid="ppat-0020113-b020">20</xref>]. Indeed, the X-ray structure of BoNT/A-LC in complex with sn2 [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>]—the C-terminal residues 141–204 of BoNT/A substrate SNAP-25—revealed an extensive array of substrate binding sites distant from the active site (exosites) that orient the substrate onto the vicinity of the active site and determine the target specificity [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>,<xref ref-type="bibr" rid="ppat-0020113-b021">21</xref>].</p>
			<p>A key step for intoxication is the translocation of endocytosed toxin across intracellular membranes to reach its cytosolic targets [<xref ref-type="bibr" rid="ppat-0020113-b003">3</xref>]. The HC likely acts as both a channel and a transmembrane chaperone for the LC protease to ensure a translocation-competent conformation during transit from acidic endosomes into the cytosol [<xref ref-type="bibr" rid="ppat-0020113-b022">22</xref>–<xref ref-type="bibr" rid="ppat-0020113-b024">24</xref>]. The details of the translocation process are largely unknown. However, available crystal structures of BoNT/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] and BoNT/B [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>] holotoxins and of BoNT/A-LC in complex with sn2 [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>] provide illuminating clues about possible mechanisms, which we consider next.</p>
			<p>The so-called translocation domain belt is a most intriguing structural feature in the crystal structures of both BoNT/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] and BoNT/B [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]: It is a loop in a mostly extended conformation (consisting of residues 492–545 for BoNT/A, and 481–532 for BoNT/B) that wraps around the catalytic domain in the structures solved at pH 7.0 and 6.0, respectively. The active site of the LC is buried ∼20 Å deep in the protein and is accessible through a negatively charged crevice, which may be partially occluded by the belt in the unreduced holotoxin. The belt is highlighted in magenta on the structure of the holotoxin/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] displayed in <xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>A. In addition, there is a second unstructured loop encompassing residues 449–491 for BoNT/A; this segment, depicted in gold, is partially apposed to the LC, perpendicular to the belt, and is parallel to the long helices of the translocation domain. The structure of the BoNT/A-LC complex with the sn2 segment [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>] is shown in <xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>B. <xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>C displays a superposition of the Cα positions of the structures of the BoNT/A-LC complex with the sn2 segment (red), the HC belt of BoNT/A (magenta), and the HC belt of BoNT/B (lime). The belt of BoNT/A is more distant to the catalytic Zn<sup>2+</sup> (distance between M<sup>530</sup> and Zn<sup>2+</sup> is ∼15 Å) than the cognate substrate (distance between Q<sup>197</sup> and Zn<sup>2+</sup> is ∼7 Å). Note the remarkable structural similarity between sn2 and the belt in the absence of stringent sequence similarity [<xref ref-type="bibr" rid="ppat-0020113-b005">5</xref>,<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]. This is relevant given the low sequence similarity (24%) of the belts among the seven BoNT serotypes and the related clostridial toxin, tetanus [<xref ref-type="bibr" rid="ppat-0020113-b005">5</xref>,<xref ref-type="bibr" rid="ppat-0020113-b025">25</xref>].</p>
			<p>What is the role of this belt?</p>
		</sec>
		<sec id="s2">
			<title>Hypothesis</title>
			<p>We propose that the belt region of the BoNT HC is a surrogate pseudosubstrate inhibitor of the LC protease and acts as a chaperone during translocation across the endosomal membrane into the cytosol. The key points are: (1) The intrinsically unstructured sn2 fragment of SNAP-25 [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>,<xref ref-type="bibr" rid="ppat-0020113-b026">26</xref>] adopts partial secondary structural elements upon binding to the LC in the binary complex crystal structure [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>] and occupies a similar position as the belt in the holotoxin crystal structures of both BoNT/A [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>] and BoNT/B [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]. (2) In analogy to other “intrinsically unstructured proteins” (IUPs) [<xref ref-type="bibr" rid="ppat-0020113-b027">27</xref>,<xref ref-type="bibr" rid="ppat-0020113-b028">28</xref>], the belt undergoes binding to its LC partner, thereby functioning as a chaperone [<xref ref-type="bibr" rid="ppat-0020113-b024">24</xref>]. (3) The belt occupies the exosites, the extensive enzyme surface allocated for substrate binding, yet it does not contain the scissile bond, thus potentially inhibiting the LC protease.</p>
		</sec>
		<sec id="s3">
			<title>Mechanism</title>
			<p>A number of plausible mechanisms can be envisioned. One, protein-assisted unfolding and pseudosubstrate-assisted refolding of the protease could be an attribute of chaperone action. There is precedence for protease inhibitors acting as intramolecular chaperones [<xref ref-type="bibr" rid="ppat-0020113-b029">29</xref>,<xref ref-type="bibr" rid="ppat-0020113-b030">30</xref>]. A case in point is subtilisin, for which propeptides, located between the signal peptide and the mature segments of the protease, function as protease inhibitors by lodging into the substrate binding pocket [<xref ref-type="bibr" rid="ppat-0020113-b030">30</xref>]. These peptides are effectively IUPs [<xref ref-type="bibr" rid="ppat-0020113-b026">26</xref>] because they lack 3-D structure in isolation, yet adopt secondary structure upon forming a complex with the cognate protease [<xref ref-type="bibr" rid="ppat-0020113-b029">29</xref>–<xref ref-type="bibr" rid="ppat-0020113-b031">31</xref>]. They are involved in the last steps of protein folding of the enzyme. The crystal structure at 2.0 Å resolution of the propeptide–subtilisin complex shows that the prosegment C-terminus (<xref ref-type="fig" rid="ppat-0020113-g002">Figure 2</xref>, magenta) binds in the enzyme active site (<xref ref-type="fig" rid="ppat-0020113-g002">Figure 2</xref>, cyan) in a product-like manner with Y<sup>77</sup> (tip of the β-strand) in the P1 binding pocket [<xref ref-type="bibr" rid="ppat-0020113-b032">32</xref>,<xref ref-type="bibr" rid="ppat-0020113-b033">33</xref>]. POIA1 (<named-content content-type="genus-species" xlink:type="simple">Pleurotus ostreatus</named-content> proteinase A inhibitor 1, PDB accession code 1ITP [<xref ref-type="bibr" rid="ppat-0020113-b034">34</xref>]), a mushroom peptide that acts as an intramolecular chaperone and inhibitor to subtilisin yet has only 18% sequence similarity to the cognate propeptide, has a similar tertiary structure to that of the propeptide of subtilisin. Similar mechanisms have been found for other bacterial proteases, including metalloproteases [<xref ref-type="bibr" rid="ppat-0020113-b029">29</xref>]. The analogy that emerges from the considerations described here for BoNT is remarkable and may be the crucial event underlying the activity of the BoNT HC belt as both an inhibitor and chaperone. However, the belt does not actually protrude into the BoNT active site. The putative inhibitory activity of the belt would therefore be restricted to the remote substrate binding interfaces of the exosites.</p>
			<fig id="ppat-0020113-g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.ppat.0030113.g002</object-id>
				<label>Figure 2</label>
				<caption>
					<title>Structure of the Subtilisin–Pro-Domain Complex</title>
					<p>The Cα backbone of subtilisin is represented as cyan ribbons and that of the pro-domain in magenta. Note that the C-terminus of the pro-domain is lodged in a crevice at the protease active site; the tip of the β-strand highlights Y<sup>77</sup> at the active site. Image rendered using subtilisin BPN' prosegment complexed with a mutant subtilisin BPN' [<xref ref-type="bibr" rid="ppat-0020113-b031">31</xref>,<xref ref-type="bibr" rid="ppat-0020113-b032">32</xref>] with YASARA [<xref ref-type="bibr" rid="ppat-0020113-b040">40</xref>].</p>
				</caption>
				<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.0030113.g002" xlink:type="simple"/>
			</fig>
			<p>Two, the belt as a continuous segment, residues 449–545 for BoNT/A, may undergo a concerted structural transition at endosomal pH with profound consequences for the translocation process [<xref ref-type="bibr" rid="ppat-0020113-b024">24</xref>]. It is conceivable that a pH-induced transition of this segment may trigger the insertion of the translocation domain into the membrane. Since the belt embraces the LC, the belt may be a structural entity that facilitates or coordinates the concerted partial unfolding of the LC at the endosomal acidic pH and directs the beginning of its translocation through the membrane.</p>
			<p>Three, a surrogate pseudosubstrate role is plausible. There is weak sequence similarity between the HC belt and sn2, which extends up to residue D<sup>195</sup> of SNAP-25 and E<sup>528</sup> of the HC belt [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>,<xref ref-type="bibr" rid="ppat-0020113-b021">21</xref>,<xref ref-type="bibr" rid="ppat-0020113-b035">35</xref>]. Furthermore, the LC undergoes autocatalytic proteolytic fragmentation [<xref ref-type="bibr" rid="ppat-0020113-b017">17</xref>,<xref ref-type="bibr" rid="ppat-0020113-b036">36</xref>], which is prevented in the presence of a competitive inhibitory peptide with a sequence of CRATKML [<xref ref-type="bibr" rid="ppat-0020113-b019">19</xref>]; this peptide closely emulates the sequence of the SNAP-25 C-terminal fragment released by proteolysis of SNAP-25 (residues 197–203 with sequence QRATKML [<xref ref-type="bibr" rid="ppat-0020113-b020">20</xref>], in which the scissile bond is between Q<sup>197</sup> and R<sup>198</sup>). However, this non-specific autocatalytic activity is known to occur only at high enzyme concentrations, such as in the context of crystallization trials, so a physiological role is questionable.</p>
			<p>It is conceivable that combinations of these three mechanisms act in concert to enhance translocation efficiency. A relevant example is the extensively studied bacterial α-lytic protease (α-LP) [<xref ref-type="bibr" rid="ppat-0020113-b037">37</xref>,<xref ref-type="bibr" rid="ppat-0020113-b038">38</xref>]. The native state of α-LP is unstable and, if unfolded, exhibits a large barrier to refold. Folding of α-LP requires the chaperone activity of its N-terminal pro-domain, which confers strong inhibition on the protease. α-LP initiates degradation of the pro-domain by proteolytic cleavage of an intervening loop at the C-end of the pro-domain, thereby releasing the α-LP from the pro-domain and allowing folding. Cleavage of α-LP pro-domain, therefore, enables efficient folding by lowering the free energy of the folded state and lowering the transition state barrier between unfolded and folded states. Upon release of the pro-domain, the kinetic barriers for unfolding dramatically increase and the α-LP becomes highly protease resistant. Concurrently, the folded state becomes destabilized yet remains kinetically trapped in its native state by a large transition state barrier. We speculate that the belt could enable efficient folding and/or unfolding akin to the α-LP pro-domain. Once it is released inside the neuron, the protease is kinetically trapped and resistant to degradation by cellular proteases or autoproteolysis, thereby implying a convergence of chaperone and surrogate substrate mechanisms. Combined with the exquisite neurotropism of BoNT conferred by its receptor-binding domain, and the target specificity and optimal catalytic efficiency endowed on its protease domain, the holotoxin emerges as a marvel of protein design.</p>
		</sec>
		<sec id="s4">
			<title>Concluding Remarks and Perspective</title>
			<p>These hypotheses naturally lead to testable questions: Is a beltless holotoxin toxic in vivo, e.g., in the context of a mouse toxicity bio-assay [<xref ref-type="bibr" rid="ppat-0020113-b039">39</xref>]? Is the belt required for channel formation? Is it required for LC translocation? Is the belt the trigger for translocation or a modulator? Are there conformational transitions upon entering the acidic environment of the endosome? The implication is that the belt region of BoNT/A HC must be subjected to a rigorous structural and functional analysis to evaluate its possible role in the translocation process, in particular with regards to a pH-induced conformational change. Accordingly, beltless variants of the HC, in which the belt region is eliminated or systematically truncated, could be recombinantly expressed, and their channel and translocation activities examined after reconstitution in lipid bilayers [<xref ref-type="bibr" rid="ppat-0020113-b024">24</xref>] and in neuronal cells [<xref ref-type="bibr" rid="ppat-0020113-b022">22</xref>,<xref ref-type="bibr" rid="ppat-0020113-b023">23</xref>] as described for the intact BoNT/A.</p>
			<p>A surrogate pseudosubstrate role of the belt could be probed by using synthetic peptides that mimic the amino acid sequence of the belt, yet incorporate SNAP-25 residues present at the toxin cleavage site as potential toxin substrates. Conversely, one could design a synthetic holotoxin in which the HC belt is replaced by the sn2 segment of SNAP-25 (<xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>B), comprising a non-cleavable bond instead of the native scissile bond. Would this chimera exhibit translocation features comparable to those of the native holotoxin?</p>
			<p>Are the belt regions truly IUPs, and do they contribute to the thermodynamic stability of the LCs? To assess whether belt peptides are true IUPs, their solution structures could be assessed with circular dichroism and nuclear magnetic resonance spectroscopies. To investigate the chaperone activity of the belt, the unfolding and refolding kinetics of LC protease could be studied in the absence and presence of peptides that imitate the belt (<xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>C) and compared to those of a complex of LC/A and sn2 (<xref ref-type="fig" rid="ppat-0020113-g001">Figure 1</xref>B). Answers to these questions could substantially improve our understanding of the most enigmatic step in the molecular mechanism of BoNT intoxication. </p>
		</sec>
		<sec id="s5">
			<title>Supporting Information</title>
			<sec id="s5a">
				<title>Accession Numbers</title>
				<p>The Protein Data Bank (PDB, <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/" xlink:type="simple">http://www.rcsb.org/pdb/</ext-link>) accession codes for the proteins discussed in this paper are BoNT/A (3BTA [<xref ref-type="bibr" rid="ppat-0020113-b004">4</xref>]), BoNT/A-LC in complex with the sn2 segment of SNAP-25 (1XTG [<xref ref-type="bibr" rid="ppat-0020113-b016">16</xref>]), BoNT/B (1EPW [<xref ref-type="bibr" rid="ppat-0020113-b006">6</xref>]), and subtilisin BPN' prosegment complexed with a mutant subtilisin BPN' (1SPB [<xref ref-type="bibr" rid="ppat-0020113-b032">32</xref>,<xref ref-type="bibr" rid="ppat-0020113-b033">33</xref>]).</p>
			</sec>
		</sec>
	</body>
	<back>
		<ack>
			<p>We thank Demet Arak, Shilpa Sambashivan, Lilia Koriazova, and Myrta Oblatt-Montal for critical reading and discussions.</p>
		</ack>
		
		<glossary>
			<title>Abbreviations</title>
			<def-list>
				<def-item>
					<term>α-LP</term>
					<def>
						<p>α-lytic protease</p>
					</def>
				</def-item>
				<def-item>
					<term>BoNT</term>
					<def>
						<p>botulinum neurotoxin</p>
					</def>
				</def-item>
				<def-item>
					<term>HC</term>
					<def>
						<p>heavy chain</p>
					</def>
				</def-item>
				<def-item>
					<term>IUP</term>
					<def>
						<p>intrinsically unstructured protein</p>
					</def>
				</def-item>
				<def-item>
					<term>LC</term>
					<def>
						<p>light chain</p>
					</def>
				</def-item>
				<def-item>
					<term>SNAP</term>
					<def>
						<p>synaptosome-associated protein</p>
					</def>
				</def-item>
				<def-item>
					<term>SNARE</term>
					<def>
						<p>soluble N-ethylmaleimide-sensitive factor attachment protein receptor</p>
					</def>
				</def-item>
			</def-list>
		</glossary>
		<ref-list>
			<title>References</title>
			<ref id="ppat-0020113-b001">
<label>1</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Arnon</surname>
							<given-names>SS</given-names>
						</name>
						<name name-style="western">
							<surname>Schechter</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Inglesby</surname>
							<given-names>TV</given-names>
						</name>
						<name name-style="western">
							<surname>Henderson</surname>
							<given-names>DA</given-names>
						</name>
						<name name-style="western">
							<surname>Bartlett</surname>
							<given-names>JG</given-names>
						</name><etal/>
					</person-group>
					<year>2001</year>
					<article-title>Botulinum toxin as a biological weapon: Medical and public health management.</article-title>
					<source>JAMA</source>
					<volume>285</volume>
					<fpage>1059</fpage>
					<lpage>1070</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b002">
<label>2</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Jankovic</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Botulinum toxin in clinical practice.</article-title>
					<source>J Neurol Neurosurg Psychiatry</source>
					<volume>75</volume>
					<fpage>951</fpage>
					<lpage>957</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b003">
<label>3</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Schiavo</surname>
							<given-names>G</given-names>
						</name>
						<name name-style="western">
							<surname>Matteoli</surname>
							<given-names>M</given-names>
						</name>
						<name name-style="western">
							<surname>Montecucco</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<year>2000</year>
					<article-title>Neurotoxins affecting neuroexocytosis.</article-title>
					<source>Physiol Rev</source>
					<volume>80</volume>
					<fpage>717</fpage>
					<lpage>766</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b004">
<label>4</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Lacy</surname>
							<given-names>DB</given-names>
						</name>
						<name name-style="western">
							<surname>Tepp</surname>
							<given-names>W</given-names>
						</name>
						<name name-style="western">
							<surname>Cohen</surname>
							<given-names>AC</given-names>
						</name>
						<name name-style="western">
							<surname>DasGupta</surname>
							<given-names>BR</given-names>
						</name>
						<name name-style="western">
							<surname>Stevens</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<year>1998</year>
					<article-title>Crystal structure of botulinum neurotoxin type A and implications for toxicity.</article-title>
					<source>Nat Struct Biol</source>
					<volume>5</volume>
					<fpage>898</fpage>
					<lpage>902</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b005">
<label>5</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Lacy</surname>
							<given-names>DB</given-names>
						</name>
						<name name-style="western">
							<surname>Stevens</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<year>1999</year>
					<article-title>Sequence homology and structural analysis of the clostridial neurotoxins.</article-title>
					<source>J Mol Biol</source>
					<volume>291</volume>
					<fpage>1091</fpage>
					<lpage>1104</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b006">
<label>6</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Swaminathan</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Eswaramoorthy</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<year>2000</year>
					<article-title>Structural analysis of the catalytic and binding sites of <named-content content-type="genus-species" xlink:type="simple">Clostridium botulinum</named-content> neurotoxin B.</article-title>
					<source>Nat Struct Biol</source>
					<volume>7</volume>
					<fpage>693</fpage>
					<lpage>699</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b007">
<label>7</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Simpson</surname>
							<given-names>LL</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Identification of the major steps in botulinum toxin action.</article-title>
					<source>Annu Rev Pharmacol Toxicol</source>
					<volume>44</volume>
					<fpage>167</fpage>
					<lpage>193</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b008">
<label>8</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Jahn</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Scheller</surname>
							<given-names>RH</given-names>
						</name>
					</person-group>
					<year>2006</year>
					<article-title>SNAREs–Engines for membrane fusion.</article-title>
					<source>Nat Rev Mol Cell Biol</source>
					<volume>7</volume>
					<fpage>631</fpage>
					<lpage>643</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b009">
<label>9</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Sutton</surname>
							<given-names>RB</given-names>
						</name>
						<name name-style="western">
							<surname>Fasshauer</surname>
							<given-names>D</given-names>
						</name>
						<name name-style="western">
							<surname>Jahn</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Brunger</surname>
							<given-names>AT</given-names>
						</name>
					</person-group>
					<year>1998</year>
					<article-title>Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution.</article-title>
					<source>Nature</source>
					<volume>395</volume>
					<fpage>347</fpage>
					<lpage>353</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b010">
<label>10</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Weber</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Zemelman</surname>
							<given-names>BV</given-names>
						</name>
						<name name-style="western">
							<surname>McNew</surname>
							<given-names>JA</given-names>
						</name>
						<name name-style="western">
							<surname>Westermann</surname>
							<given-names>B</given-names>
						</name>
						<name name-style="western">
							<surname>Gmachl</surname>
							<given-names>M</given-names>
						</name><etal/>
					</person-group>
					<year>1998</year>
					<article-title>SNAREpins: Minimal machinery for membrane fusion.</article-title>
					<source>Cell</source>
					<volume>92</volume>
					<fpage>759</fpage>
					<lpage>772</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b011">
<label>11</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Jahn</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Lang</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Sudhof</surname>
							<given-names>TC</given-names>
						</name>
					</person-group>
					<year>2003</year>
					<article-title>Membrane fusion.</article-title>
					<source>Cell</source>
					<volume>112</volume>
					<fpage>519</fpage>
					<lpage>533</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b012">
<label>12</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Agarwal</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Binz</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Swaminathan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>Structural analysis of botulinum neurotoxin serotype F light chain: Implications on substrate binding and inhibitor design.</article-title>
					<source>Biochemistry</source>
					<volume>44</volume>
					<fpage>11758</fpage>
					<lpage>11765</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b013">
<label>13</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Agarwal</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Eswaramoorthy</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Kumaran</surname>
							<given-names>D</given-names>
						</name>
						<name name-style="western">
							<surname>Binz</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Swaminathan</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212–&gt;Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway.</article-title>
					<source>Biochemistry</source>
					<volume>43</volume>
					<fpage>6637</fpage>
					<lpage>6644</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b014">
<label>14</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Arndt</surname>
							<given-names>JW</given-names>
						</name>
						<name name-style="western">
							<surname>Chai</surname>
							<given-names>Q</given-names>
						</name>
						<name name-style="western">
							<surname>Christian</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Stevens</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<year>2006</year>
					<article-title>Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: Repercussions for VAMP-2 substrate specificity.</article-title>
					<source>Biochemistry</source>
					<volume>45</volume>
					<fpage>3255</fpage>
					<lpage>3262</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b015">
<label>15</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Arndt</surname>
							<given-names>JW</given-names>
						</name>
						<name name-style="western">
							<surname>Yu</surname>
							<given-names>W</given-names>
						</name>
						<name name-style="western">
							<surname>Bi</surname>
							<given-names>F</given-names>
						</name>
						<name name-style="western">
							<surname>Stevens</surname>
							<given-names>RC</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>Crystal structure of botulinum neurotoxin type G light chain: Serotype divergence in substrate recognition.</article-title>
					<source>Biochemistry</source>
					<volume>44</volume>
					<fpage>9574</fpage>
					<lpage>9580</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b016">
<label>16</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Breidenbach</surname>
							<given-names>MA</given-names>
						</name>
						<name name-style="western">
							<surname>Brunger</surname>
							<given-names>AT</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Substrate recognition strategy for botulinum neurotoxin serotype A.</article-title>
					<source>Nature</source>
					<volume>432</volume>
					<fpage>925</fpage>
					<lpage>929</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b017">
<label>17</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Segelke</surname>
							<given-names>B</given-names>
						</name>
						<name name-style="western">
							<surname>Knapp</surname>
							<given-names>M</given-names>
						</name>
						<name name-style="western">
							<surname>Kadkhodayan</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Balhorn</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Rupp</surname>
							<given-names>B</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Crystal structure of <named-content content-type="genus-species" xlink:type="simple">Clostridium botulinum</named-content> neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity.</article-title>
					<source>Proc Natl Acad Sci U S A</source>
					<volume>101</volume>
					<fpage>6888</fpage>
					<lpage>6893</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b018">
<label>18</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Rossetto</surname>
							<given-names>O</given-names>
						</name>
						<name name-style="western">
							<surname>Schiavo</surname>
							<given-names>G</given-names>
						</name>
						<name name-style="western">
							<surname>Montecucco</surname>
							<given-names>C</given-names>
						</name>
						<name name-style="western">
							<surname>Poulain</surname>
							<given-names>B</given-names>
						</name>
						<name name-style="western">
							<surname>Deloye</surname>
							<given-names>F</given-names>
						</name><etal/>
					</person-group>
					<year>1994</year>
					<article-title>SNARE motif and neurotoxins.</article-title>
					<source>Nature</source>
					<volume>372</volume>
					<fpage>415</fpage>
					<lpage>416</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b019">
<label>19</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Schmidt</surname>
							<given-names>JJ</given-names>
						</name>
						<name name-style="western">
							<surname>Stafford</surname>
							<given-names>RG</given-names>
						</name>
						<name name-style="western">
							<surname>Bostian</surname>
							<given-names>KA</given-names>
						</name>
					</person-group>
					<year>1998</year>
					<article-title>Type A botulinum neurotoxin proteolytic activity: Development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite.</article-title>
					<source>FEBS Lett</source>
					<volume>435</volume>
					<fpage>61</fpage>
					<lpage>64</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b020">
<label>20</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Vaidyanathan</surname>
							<given-names>VV</given-names>
						</name>
						<name name-style="western">
							<surname>Yoshino</surname>
							<given-names>K</given-names>
						</name>
						<name name-style="western">
							<surname>Jahnz</surname>
							<given-names>M</given-names>
						</name>
						<name name-style="western">
							<surname>Dorries</surname>
							<given-names>C</given-names>
						</name>
						<name name-style="western">
							<surname>Bade</surname>
							<given-names>S</given-names>
						</name><etal/>
					</person-group>
					<year>1999</year>
					<article-title>Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme- substrate complexes and cleavage.</article-title>
					<source>J Neurochem</source>
					<volume>72</volume>
					<fpage>327</fpage>
					<lpage>337</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b021">
<label>21</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Breidenbach</surname>
							<given-names>MA</given-names>
						</name>
						<name name-style="western">
							<surname>Brunger</surname>
							<given-names>AT</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>New insights into clostridial neurotoxin-SNARE interactions.</article-title>
					<source>Trends Mol Med</source>
					<volume>11</volume>
					<fpage>377</fpage>
					<lpage>381</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b022">
<label>22</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Fischer</surname>
							<given-names>A</given-names>
						</name>
						<name name-style="western">
							<surname>Montal</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<year>2006</year>
					<article-title>Characterization of <named-content content-type="genus-species" xlink:type="simple">Clostridial botulinum</named-content> neurotoxin channels in neuroblastoma cells.</article-title>
					<source>Neurotox Res</source>
					<volume>9</volume>
					<fpage>93</fpage>
					<lpage>100</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b023">
<label>23</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Fischer</surname>
							<given-names>A</given-names>
						</name>
						<name name-style="western">
							<surname>Montal</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<year>2007</year>
					<article-title>Single molecule detection of intermediates during Botulinum neurotoxin translocation across membranes.</article-title>
					<source>Proc Natl Acad Sci U S A</source>
					<volume>104</volume>
					<fpage>10447</fpage>
					<lpage>10452</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b024">
<label>24</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Koriazova</surname>
							<given-names>LK</given-names>
						</name>
						<name name-style="western">
							<surname>Montal</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<year>2003</year>
					<article-title>Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.</article-title>
					<source>Nat Struct Biol</source>
					<volume>10</volume>
					<fpage>13</fpage>
					<lpage>18</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b025">
<label>25</label>
				<element-citation publication-type="other" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Drummond</surname>
							<given-names>AJ</given-names>
						</name>
						<name name-style="western">
							<surname>Ashton</surname>
							<given-names>B</given-names>
						</name>
						<name name-style="western">
							<surname>Heled</surname>
							<given-names>J</given-names>
						</name>
						<name name-style="western">
							<surname>Kearse</surname>
							<given-names>M</given-names>
						</name>
						<name name-style="western">
							<surname>Moir</surname>
							<given-names>R</given-names>
						</name><etal/>
					</person-group>
					<year>2006</year>
					<source>Geneious version 2.5.4</source>
					<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.geneious.com/" xlink:type="simple">http://www.geneious.com/</ext-link>. Accessed 25 August 2007.</comment>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b026">
<label>26</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Fasshauer</surname>
							<given-names>D</given-names>
						</name>
						<name name-style="western">
							<surname>Bruns</surname>
							<given-names>D</given-names>
						</name>
						<name name-style="western">
							<surname>Shen</surname>
							<given-names>B</given-names>
						</name>
						<name name-style="western">
							<surname>Jahn</surname>
							<given-names>R</given-names>
						</name>
						<name name-style="western">
							<surname>Brunger</surname>
							<given-names>AT</given-names>
						</name>
					</person-group>
					<year>1997</year>
					<article-title>A structural change occurs upon binding of syntaxin to SNAP-25.</article-title>
					<source>J Biol Chem</source>
					<volume>272</volume>
					<fpage>4582</fpage>
					<lpage>4590</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b027">
<label>27</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Dyson</surname>
							<given-names>HJ</given-names>
						</name>
						<name name-style="western">
							<surname>Wright</surname>
							<given-names>PE</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>Intrinsically unstructured proteins and their functions.</article-title>
					<source>Nat Rev Mol Cell Biol</source>
					<volume>6</volume>
					<fpage>197</fpage>
					<lpage>208</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b028">
<label>28</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Tompa</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>The interplay between structure and function in intrinsically unstructured proteins.</article-title>
					<source>FEBS Lett</source>
					<volume>579</volume>
					<fpage>3346</fpage>
					<lpage>3354</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b029">
<label>29</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Shinde</surname>
							<given-names>U</given-names>
						</name>
						<name name-style="western">
							<surname>Fu</surname>
							<given-names>X</given-names>
						</name>
						<name name-style="western">
							<surname>Inouye</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<year>1999</year>
					<article-title>A pathway for conformational diversity in proteins mediated by intramolecular chaperones.</article-title>
					<source>J Biol Chem</source>
					<volume>274</volume>
					<fpage>15615</fpage>
					<lpage>15621</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b030">
<label>30</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Shinde</surname>
							<given-names>UP</given-names>
						</name>
						<name name-style="western">
							<surname>Liu</surname>
							<given-names>JJ</given-names>
						</name>
						<name name-style="western">
							<surname>Inouye</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<year>1997</year>
					<article-title>Protein memory through altered folding mediated by intramolecular chaperones.</article-title>
					<source>Nature</source>
					<volume>389</volume>
					<fpage>520</fpage>
					<lpage>522</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b031">
<label>31</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Kojima</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Iwahara</surname>
							<given-names>A</given-names>
						</name>
						<name name-style="western">
							<surname>Yanai</surname>
							<given-names>H</given-names>
						</name>
					</person-group>
					<year>2005</year>
					<article-title>Inhibitor-assisted refolding of protease: A protease inhibitor as an intramolecular chaperone.</article-title>
					<source>FEBS Lett</source>
					<volume>579</volume>
					<fpage>4430</fpage>
					<lpage>4436</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b032">
<label>32</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Bryan</surname>
							<given-names>P</given-names>
						</name>
						<name name-style="western">
							<surname>Wang</surname>
							<given-names>L</given-names>
						</name>
						<name name-style="western">
							<surname>Hoskins</surname>
							<given-names>J</given-names>
						</name>
						<name name-style="western">
							<surname>Ruvinov</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Strausberg</surname>
							<given-names>S</given-names>
						</name><etal/>
					</person-group>
					<year>1995</year>
					<article-title>Catalysis of a protein folding reaction: Mechanistic implications of the 2.0 A structure of the subtilisin-prodomain complex.</article-title>
					<source>Biochemistry</source>
					<volume>34</volume>
					<fpage>10310</fpage>
					<lpage>10318</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b033">
<label>33</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Gallagher</surname>
							<given-names>T</given-names>
						</name>
						<name name-style="western">
							<surname>Gilliland</surname>
							<given-names>G</given-names>
						</name>
						<name name-style="western">
							<surname>Wang</surname>
							<given-names>L</given-names>
						</name>
						<name name-style="western">
							<surname>Bryan</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<year>1995</year>
					<article-title>The prosegment-subtilisin BPN' complex: Crystal structure of a specific ‘foldase'.</article-title>
					<source>Structure</source>
					<volume>3</volume>
					<fpage>907</fpage>
					<lpage>914</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b034">
<label>34</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Sasakawa</surname>
							<given-names>H</given-names>
						</name>
						<name name-style="western">
							<surname>Yoshinaga</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Kojima</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Tamura</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<year>2002</year>
					<article-title>Structure of POIA1, a homologous protein to the propeptide of subtilisin: Implication for protein foldability and the function as an intramolecular chaperone.</article-title>
					<source>J Mol Biol</source>
					<volume>317</volume>
					<fpage>159</fpage>
					<lpage>167</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b035">
<label>35</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Chen</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Kim</surname>
							<given-names>JJ</given-names>
						</name>
						<name name-style="western">
							<surname>Barbieri</surname>
							<given-names>JT</given-names>
						</name>
					</person-group>
					<year>2007</year>
					<article-title>Mechanism of substrate recognition by botulinum neurotoxin serotype A.</article-title>
					<source>J Biol Chem</source>
					<volume>282</volume>
					<fpage>9621</fpage>
					<lpage>9627</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b036">
<label>36</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Ahmed</surname>
							<given-names>SA</given-names>
						</name>
						<name name-style="western">
							<surname>Byrne</surname>
							<given-names>MP</given-names>
						</name>
						<name name-style="western">
							<surname>Jensen</surname>
							<given-names>M</given-names>
						</name>
						<name name-style="western">
							<surname>Hines</surname>
							<given-names>HB</given-names>
						</name>
						<name name-style="western">
							<surname>Brueggemann</surname>
							<given-names>E</given-names>
						</name><etal/>
					</person-group>
					<year>2001</year>
					<article-title>Enzymatic autocatalysis of botulinum A neurotoxin light chain.</article-title>
					<source>J Protein Chem</source>
					<volume>20</volume>
					<fpage>221</fpage>
					<lpage>231</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b037">
<label>37</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Cunningham</surname>
							<given-names>EL</given-names>
						</name>
						<name name-style="western">
							<surname>Agard</surname>
							<given-names>DA</given-names>
						</name>
					</person-group>
					<year>2004</year>
					<article-title>Disabling the folding catalyst is the last critical step in alpha-lytic protease folding.</article-title>
					<source>Protein Sci</source>
					<volume>13</volume>
					<fpage>325</fpage>
					<lpage>331</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b038">
<label>38</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Jaswal</surname>
							<given-names>SS</given-names>
						</name>
						<name name-style="western">
							<surname>Sohl</surname>
							<given-names>JL</given-names>
						</name>
						<name name-style="western">
							<surname>Davis</surname>
							<given-names>JH</given-names>
						</name>
						<name name-style="western">
							<surname>Agard</surname>
							<given-names>DA</given-names>
						</name>
					</person-group>
					<year>2002</year>
					<article-title>Energetic landscape of alpha-lytic protease optimizes longevity through kinetic stability.</article-title>
					<source>Nature</source>
					<volume>415</volume>
					<fpage>343</fpage>
					<lpage>346</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b039">
<label>39</label>
				<element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author">
						<name name-style="western">
							<surname>Eubanks</surname>
							<given-names>LM</given-names>
						</name>
						<name name-style="western">
							<surname>Hixon</surname>
							<given-names>MS</given-names>
						</name>
						<name name-style="western">
							<surname>Jin</surname>
							<given-names>W</given-names>
						</name>
						<name name-style="western">
							<surname>Hong</surname>
							<given-names>S</given-names>
						</name>
						<name name-style="western">
							<surname>Clancy</surname>
							<given-names>CM</given-names>
						</name><etal/>
					</person-group>
					<year>2007</year>
					<article-title>An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.</article-title>
					<source>Proc Natl Acad Sci U S A</source>
					<volume>104</volume>
					<fpage>2602</fpage>
					<lpage>2607</lpage>
				</element-citation>
			</ref>
			<ref id="ppat-0020113-b040">
<label>40</label>
				<element-citation publication-type="other" xlink:type="simple">
					<collab xlink:type="simple">YASARA Biosciences</collab>
					<year>2007</year>
					<source>YASARA: Yet another scientific artificial reality application</source>
					<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.yasara.org/" xlink:type="simple">http://www.yasara.org/</ext-link>. Accessed 25 August 2007.</comment>
				</element-citation>
			</ref>
		</ref-list>
	</back>
</article>